Literature DB >> 6367046

Biological activity of recombinant human interleukin-2 produced in Escherichia coli.

S A Rosenberg, E A Grimm, M McGrogan, M Doyle, E Kawasaki, K Koths, D F Mark.   

Abstract

The gene for interleukin-2 was isolated from the Jurkat cell line and from normal peripheral blood lymphocytes and, when inserted in Escherichia coli, was expressed at high concentrations. This interleukin-2 was purified to apparent homogeneity and tested for biological activity in a variety of assays in vitro and in vivo. The recombinant lymphokine supports the growth of murine and human interleukin-2 dependent cell lines, enhances the generation of murine and human cytolytic cells in vitro, and generates lymphokine activated killer cells from murine and human lymphocytes. It has a serum half-life of 2 to 3 minutes in the mouse and significantly enhances the generation of cytolytic cells in vivo after alloimmunization. No functional differences between native and the recombinant interleukin-2 molecules have been detected.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6367046     DOI: 10.1126/science.6367046

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  158 in total

1.  Development of effective immunotherapy for the treatment of patients with cancer.

Authors:  Steven A Rosenberg
Journal:  J Am Coll Surg       Date:  2004-05       Impact factor: 6.113

2.  Potentiated lymphokine-activated killer cell activity generated by low-dose interleukin-2 and mismatched double-stranded RNA.

Authors:  H R Hubbell; G D Gibson; R D Bigler
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

Review 3.  Raising the bar: the curative potential of human cancer immunotherapy.

Authors:  Steven A Rosenberg
Journal:  Sci Transl Med       Date:  2012-03-28       Impact factor: 17.956

4.  A new human pancreatic carcinoma cell line developed for adoptive immunotherapy studies with lymphokine-activated killer cells in nude mice.

Authors:  B J Drucker; F M Marincola; D Y Siao; T A Donlon; C D Bangs; W D Holder
Journal:  In Vitro Cell Dev Biol       Date:  1988-12

5.  Limiting-dilution analysis of T cells extracted from solid human lung tissue: comparison of precursor frequencies for proliferative responses and lymphokine production between lung and blood T cells from individual donors.

Authors:  P G Holt; U R Kees; M A Shon-Hegrad; A Rose; J Ford; N Bilyk; R Bowman; B W Robinson
Journal:  Immunology       Date:  1988-08       Impact factor: 7.397

6.  TGF-beta inhibits the in vitro induction of lymphokine-activated killing activity.

Authors:  E A Grimm; W L Crump; A Durett; J P Hester; S Lagoo-Deenadalayan; L B Owen-Schaub
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

7.  Interleukin 2 receptor bearing T lymphocytes in patients with chronic liver disease.

Authors:  S Kakumu; K Yoshioka; A Fuji; H Tahara
Journal:  Gastroenterol Jpn       Date:  1988-08

8.  A phase I trial of intraperitoneal recombinant interleukin 2 in patients with ovarian carcinoma.

Authors:  P B Chapman; J E Kolitz; T B Hakes; J L Gabrilove; K Welte; V J Merluzzi; A Engert; E C Bradley; M Konrad; R Mertelsmann
Journal:  Invest New Drugs       Date:  1988-09       Impact factor: 3.850

9.  Combination therapy with a synthetic peptide of C-reactive protein and interleukin 2: augmented survival and eradication of pulmonary metastases.

Authors:  B P Barna; M J Thomassen; M Maier; S V Medendorp; R R Tubbs; T Chiang; P Zhou; B Yen-Lieberman; S Singh-Burgess; S D Deodhar
Journal:  Cancer Immunol Immunother       Date:  1994-01       Impact factor: 6.968

10.  Interleukin 2 regulates Raf-1 kinase activity through a tyrosine phosphorylation-dependent mechanism in a T-cell line.

Authors:  B C Turner; N K Tonks; U R Rapp; J C Reed
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.